Download the ESMO 2012 Abstract Book - Oxford Journals

More documents

Recommendations

Info

Annals Of Oncology translational research index CXCL14: 925P CXCL3: 228P CXCL9: 865P CXCR4: 1033P CXCR7: 1688PD Cyclin D1: 165, 483P, 1026P, 1027P, 1031P, 1118PD, 1700 Cyclin dependent kinases: 543P, 769 Cyclin E1: 769 Cycline H: 527PD CYFRA 21-1: 1310P CYFRA: 505, 1203P Cyp P450 2D6: 1034P CYP1: 17IN CYP11A1: 928P CYP17: 325PD, 925P, 927P, 946 CYP17A1: 48IN CYP1A1: 374P, 724P CYP1A2: 850P CYP2C19: 1293P CYP2C9: 850P, 1667P CYP2D6: 17IN, 129IN, 189P, 196P, 295P CYP3A: 1678P CYP3A4: 291P, 1293P, 1578P, 1667P CYP3A5: 724P, 1667P Cytochrome P450: 506, 873, 1618P D2: 129IN DAPK1: 221P DAXX: 12IN DDR: 61IN, 81IN, 102IN, 119IN DDX3X: 25IN, 159P DEPDC1: 1671P DHEA: 277P DHFR: 1211 DHH: 720P DLC1: 221P, 1701 DLD30: 245O DLL4: 642 DNA: 2IN, 10IN, 11IN, 20IN, 42IN, 5OIN, 61IN, 86IN, 96IN, 116IN, 149P, 150P, 156P, 161P, 168O, 171O, 185P, 22OP, 221P, 225P, 240, 245O, 293P, 376, 397, 428P, 435TiP, 484P, 516P, 518O, 527PD, 537P, 543P, 544P, 548P, 549P, 613P, 656, 666O, 686P, 703P, 699P, 806P, 812P, 813P, 85OP, 920P, 964TiP, 968O, 971PD, 988P, 1025P, 1028P, 1032P, 1052, 1118PD, 1119PD, 1121P, 1122P, 1123P, 1135P, 1139P, 1145, 1147, 1192PD, 1242P, 1244P, 1266P, 1273P, 1315, 1316, 1339, 1393P, 1649P, 1651P, 1662P, 1664P, 1677P, 1679P, 1686P DPD: 550P, 1211 DPYSL: 1701 DR5: 662TiP D-SER: 483P DTX2: 215P DWS: 1032P Dysadherin: 838P E1: 277P E2: 277P E6: 62IN E7: 62IN EBER: 1026P EC: 861P E-cadherin: 145P, 483P, 511PD, 548P, 675P, 838P, 1026P, 1693P, 1695P, 1700 ECSCR: 178P EGF: 536P, 544P, 742P, 1464P, 1652P, 1668P EGFR: 6IN, 7IN, 19IN, 24IN, 28IN, 29IN, 58IN, 60IN, 62IN, 63IN, 78IN, 81IN, 82IN, 83IN, 85IN, 90IN, 105IN, 106IN, 119IN, 138IN, 143PD, 158P, 170O, 179P, 180P, 182P, 183P, 190P, 194P, 211P, 213P, 218P, 232, 234, 237, 257P, 343P, 347P, 353P, 412O, 438O, 439O, 467P, 509TiP, 525PD, 526PD, 533P, 535P, 536P, 537P, 544P, 549P, 558P, 563P, 570P, 578P, 597P, 605P, 606P, 630, 631, 641, 664TIP, 665TIP, 667PD, 720P, 868, 970PD, 1016O, 1017O, 1021PD, 1026P, 1027P, 1029P, 1031P, 1036P, 1145, 1176P, 1187P, 1190P, 1193P, 1197P, 1198P, 1209, 1211, 1218, 1226O, 1227O, 1228O, 1229PD, 1232PD, 1251P, 1252P, 1254P, 1255P, 1257P, 1258P, 1259P, 1260P, 1261P, 1262P,1263P, 1264P, 1265P, 1266P, 1269P, 1270P, 1271P, 1272P, 1273P, 1274P, 1277P, 1280P, 1282P, 1283P, 1284P, 1286P, 1288P, 1289P, 1291P, 1292P, 1293P, 1295P, 1300P, 1302P, 1309P, 1310P, 1311P, 1313, 1315, 1316, 1318, 1323, 1325, 1328, 1330, 1331, 1333,1336, 1338, 1339, 1340, 1342, 1343, 1344, 1345, 1346, 1347, 1348, 1362TiP, 1366TiP, 1367TiP, 1396P, 1530P, 1644PD, 1649P, 1651P, 1652P, 1655P, 1659P, 1662P, 1666P, 1668P, 1690P, 1692P, 1701 ELAM-1: 732P EML4: 81IN, 108IN, 119IN, 195P, 1187P, 1193P, 1195P, 1208, 1324 EOMES: 71IN EP4: 1033P EPAS-1: 354P EpCAM: 217P, 472P, 495P, 911P, 1175P, 1313, 1512, 1650P, 1696P EPHA4: 1691P Epiregulin: 526PD, 536P, 1027P ER: 14IN, 15IN, 19IN, 21IN, 151P, 172O, 176PD, 197P, 199P, 201P, 205P, 206P, 216P, 245O, 247O, 248O, 249PD, 252PD, 257P, 258P, 259P, 264P, 265P, 266P, 278P, 279P, 283P, 284P, 288P, 289P, 291P, 294P, 298P, 299, 301, 302, 305, 308, 309, 323PD, 325PD, 336P, 340P, 343P, 345P, 347P, 350P, 353P, 362P, 368P, 370P, 372P, 373P, 376, 377, 378, 381, 384, 386, 397, 399, 406TIP, 414PD, 513PD, 923P, 11090P, 1397P, 1398P, 1656P, 1702 ERCC1: 7IN, 77IN, 187P, 207P, 524P, 527PD, 613P, 628, 803P, 990P, 1026P, 1052, 1170P, 1193P, 1211, 1226O, 1244P, 1645PD Erk: 108IN, 119IN, 153P, 456P, 475P, 483P, 1075P, 1349, 1491P, 1647PD, 1652P, 1668P ERP29: 1032P, 1119P E-selectin: 791PD, 833P, 1236PD, 1657P ESR1: 17IN ESR2: 17IN ETPA: 1701 EWS/FLI1: 92IN EXE: 324PD EZH2: 208P, 1066PD F3: 906P FAK: 179P, 384, 1027P, 1659P FASCIN-1: 1026P FC: 64IN FCGR: 237 FCyR: 472P, 495P FGF: 20IN, 52IN, 319O, 822P, 966O FGFR: 7IN, 50IN, 81IN, 119IN, 181P, 319O, 417PD, 446PD, 737P, 744P, 814P, 81TIP FHIT: 675P FLAGS: 668PD FLR-B/FOX: 629 FLT: 115IN, 1066PD,1067PD, 1194P, 1479PD FOXA1: 23P FOXL2: 993P FOXO3a: 185P FOXP3: 939P, 1314 FPGH: 1211 FPGS: 1211 FRAP1: 812P FYC: 102IN GARFT: 1211 Gata3:71IN, 102IN G-CSF: 246O, 1085P GDNF: 225P GGH: 542P GHRL2: 223P, 465P GLI1: 1309P, 1663P, 1693P GLUT1: 166, 562P, 1033P, 1180PD GLUT2: 166 GM-CSF: 723P, 813P, 943P, 1672P GNAS: 12IN, 227P GRIN2A: 11IN GRM3: 11IN GSK-3: 156P, 1026P GSTM1: 1078P GSTT1: 1078P H2AX: 435TIP H3: 442O H-cadherin: 548P HDI: 150P Hedgehog: 62IN, 63IN, 449PD, 463P, 720P, 1111PD, 1112PD, 1309P, 1663P, 1694P HENT1: 709P HER2: 7 IN, 15IN, 19IN, 21IN, 28IN, 44IN, 50IN, 57IN, 78IN, 81IN, 83IN, 102IN, 103IN, 104IN, 108IN, 119IN, 121IN, 172O, 180P,197P, 199P, 201P, 202P, 205P, 206P, 216P, 217P, 228P, 231P, 241, 243, 245O, 246O, 248O, 252PD, 254PD, 255PD, 257P, 258P, 259P, 264P, 265P, 266P, 267P, 268P, 269P, 270P, 271P, 272P, 274P, 275P, 276P, 278P, 279P, 283P, 284P, 286P, 288P, 289P, 291P, 292P, 294P, 298P, 299, 300, 301, 303, 304, 308, 309, 315TIP, 316TIP, 317O, 318O, 319O, 320PD, 321PD, 322PD, 323PD, 324PD, 325PD, 336P, 342P, 343P, 344P, 345P, 346P, 347P, 352P, 353P, 356P, 357P, 362P, 364P, 365P, 366P, 368P, 370P, 373P, 377, 378, 379, 380, 381, 386, 387, 389, 391, 392, 395, 396, 397, 399, 402, 404, 406TIP, 407TIP, 408TIP, 409TIP, 414PD, 446PD, 454P, 458P, 464P, 467P, 470P, 476P, 494P, 496P, 509TiP, 513PD, 515P, 675P, 677P, 678P, 699P, 703P, 720P, 750, 762, 768O, 970PD, 974PD, 1142P, 1185P, 1228O, 1232PD, 1252P, 1288P, 1290P, 1311P, 1313, 1322, 1397P, 1398P, 1450P, 1646PD, 1647PD, 1656P, 1657P, 1659P, 1664P, 1675P, 1698P, 1702 HER3: 7IN, 202P, 214P, 226P, 231P, 343P, 467P, 496P, 720P, 970PD, 974PD, 1185P, 1690P HER4: 7IN, 11IN, 50TiP, 970PD, 1185P, 1228O, 1252P HGF: 70IN, 143PD, 205P, 222P, 443PD, 444PD, 669PD, 687P, 720P, 791PD, 833P, 1291P, 1365TIP HIF: 109IN, 156P, 354P, 532P, 751, 794PD, 830P, 832P, 835P, 869, 1033P, 1170P, 1180PD, 1685P HIPEC: 774 HK II: 166, 1033P HLA-A24: 460P HLA-A2402: 1671P HLA-DR: 197P HMGB1: 495P HMOX-1: 971PD HOX: 147P, 223P HRAS: 1311P HSP27: 900PD HSP90: 7IN, 57IN, 61IN, 66IN, 156P, 215P, 347P, 438O, 922P, 1332, 1679P HXR3: 988P ICAM: 431, 1236PD, 1657P ICOS: 71IN Volume 23 | Supplement 9 | September <strong>2012</strong> doi:10.1093/annonc/mds480 | ix605 translational research index
translational research index translational research index IDH: 23IN, 421P, 1701 IFI16: 1701 IFN alpha: 224P IFN gama: 163P, 622, 865P IFN: 503 IGF: 90IN, 202P, 776TIP IGFBP3: 92IN, 411O, 906P, 1030P IGFR: 13IN, 90IN, 217P, 301, 606P, 776TIP, 830P, 917P, 1030P, 1319, 1322, 1497P, 1668P, 1703IN IGluR: 11IN IHH: 720P IKBA: 148P IKBKAP: 1032P, 1119P IL-10: 190P, 1464P, 1672P IL-12: 17IN, 163P, 222P, 1672P IL-13: 480P IL-17: 17IN, 71IN, 150P, 480P IL-1B: 473P, 480P IL-2: 224P, 723P IL-22: 480P IL-23: 150P IL-2RA: 865P IL-4: 480P, 510TiP, 1314, 1672P IL-5: 480P IL-6: 153P, 165, 222P, 228P, 354P, 476P, 720P, 791PD, 833P, 1088P, 1464P, 1693P IL-7: 813P IL-8: 52IN, 190P, 222P, 354P, 732P, 791PD, 1194P, 1464P, 1657P ILKAP: 1701 IL-RB2: 17IN INI1: 92IN Integrin b1: 179P IPO8: 1701 IRF4: 66IN, JAK: 102IN, 483P KDM6A: 25IN KDR: 7IN, 266P Ki-67: 13IN, 15IN, 19IN, 71IN, 73IN, 102IN, 191P, 200P, 201P, 233, 268P, 270P, 276P, 281P, 284P, 303, 305, 306, 343P, 364P, 366P, 406TiP, 442O, 443PD, 457P, 538P, 562P, 575P, 1026P, 1158P, 1160P, 1164P, 1167P, 1695P KIF22: 1701 KIF5B: 119IN KIT: 19IN, 92IN, 94IN, 102IN, 174O, 222P, 227P, 244, 385, 417PD, 705P, 706P, 707P, 708P, 737P, 814P, 880, 1067PD, 1118PD, 1123P, 1157O, 1478O, 1479PD, 1486PD, 1489P, 1491P, 1516, 1541, 1679P KIAA0664: 1701 KLC1: 119IN KLF7: 225P KLK: 223P KOC1: 460P, 1671P KRAS: 6IN, 7IN, 12IN, 28IN, 78IN, 83IN, 119IN, 143PD, 170O, 180P, 207P, 208P, 21OP, 211P, 214P, 218P, 237, 438O, 442O, 475P, 520O, 525PD, 526PD, 532P, 533P, 535P, 536P, 537P, 543P, 548P, 549P, 555P, 557P, 558P, 561P, 564P, 565P, 568P, 570P, 574P, 580P, 582P, 587P, 593P, 594P, 597P, 598P, 605P, 606P, 608P, 629, 630, 631, 641,643, 647, 649, 651, 653, 665TiP, 667PD, 696P, 703P, 720P, 1017O, 1187P, 1190P, 1193P, 1226O, 1233PD, 1248P, 1266P, 1282P, 1302P, 1307P, 1311P, 1315, 1316, 1322, 1339, 1349, 1362TiP, 1366TiP, 1647PD, 1649P, 1652P, 1654P, 1664P, 1701 KYNU: 1701 LAP3: 1701 LDHA: 1033P Lea: 619 LEF1: 1032P Leptin: 190P, 473P, 483P, 1603P Lex: 619 Ley: 619 LGR5: 720P LINE1: 225P LKB1: 180B LMO4: 1655P LMP1: 221P, 1027P LRIG: 544P LRRK2: 51IN LTK: 102IN MA2K1: 1030P MAGE: 1182P Mamaglobin: 304 MAP: 102IN, 154P MAP1B: 1701 MAP2K4: 102IN MAP3K1: 102IN MAPK: 119IN, 143PD, 154P, 173O, 348P, 451P, 475P, 483P, 483P, 869, 1026P, 1030P, 1075P, 1039P, 1185P, 1659P, 1668P, 1674P, 1693P MAPT: 1026P Matrix metalloproteinases (MMPs): 384, 617 MCC: 1032P MCL-1: 1027P MCM2: 240 MCMs: 240 MCPH1: 1662P MCT1: 1033P MDC1: 686P, 1661P, 1662P MDM2: 7IN, 92IN, 93IN, 156P, 1122P MDR1: 196P MEK: 11IN, 90IN, 108IN, 119IN, 143PD, 154P, 173O, 451P, 456P, 475P, 609P, 147P, 1124P, 1193P, 1197P, 1349, 1647PD, 1674P Merlin protein: 419PD MGMT: 23IN, 24IN, 416PD, 421P, 424P, 435TiP, 548P, 830P, 1676P MICA: 160P, 1690P MINT: 225P, 543P MIP1: 224P, 865P miRNA: 60IN, 143PD, 145P, 148P, 149P, 150P, 159P, 160P, 169O, 178P, 188P, 202P, 205P, 215P, 223P, 226P, 250PD, 305, 385, 426P, 525P, 535P, 542P, 615, 686P, 723P, 807P, 1025P, 1027P, 1030P, 1031P, 1139P, 1170P, 1242P, 1243P, 1309P, 1312, 1532P, 1646PD, 1653P, 1655P, 1661P, 1672P, 1679P, 1682P, 1693P Mismatch repair deficiency (dMMR): 516P, 521O, 524P, 703P MLH1: 516P, 543P, 703P, 720P, 1311P MLL2: 25IN, 102IN MMP-1: 287P MMP-2: 146P, 384, 794PD, 1682P MMP-3: 224P MMP-7: 1700 MMP-8: 910P MMP-9: 146P, 384, 545P, 617 MMSET: 686P, 1661P MPHOSPH1: 1671P MSH2: 7IN, 516P, 703P, 720P MSH3: 720P MSH6: 516P, 703P MSI-H: 656, 675P MSN: 1701 MSP: 1532P MST1R: 1532P MST2: 1684P MT: 1203P MTHFR: 640, 1244P, 1326 Annals Of Oncology mTOR: 2IN,13IN, 52IN, 57IN, 65IN, 76IN, 83IN, 90IN, 92IN, 107IN, 108IN, 130IN, 154P, 173O, 185P, 236, 318O, 324PD, 350P, 352P, 405TiP, 419PD, 420PD, 442O, 450PD, 452P, 454P, 462P, 532P, 717P, 781TiP, 783O, 798PD, 812P, 814P, 818P, 819P, 822P, 823P, 828P, 837P, 839P, 840P, 841P, 845P, 846P, 849P, 852P, 869, 873, 879, 881, 890TiP, 917P, 1017O, 1026P, 1031P, 1154O, 1156O, 1157O, 1491P, 1107TiP, 1162P, 1165P, 1685P, 1703IN MUC1: 619, 622, 723P MUC2: 619, 719P MUC5AC: 619 MUC6: 720P MVD: 1236PD MYC: 102IN, 202P, 490P, 832P, 916P, 1185P, 1210, 1700 MYH9: 102IN MYST1: 215P NANOG: 149P, 604P N-cadherin: 1695P NeuGc-GM3: 1238PD Neurokinin receptor: 1550PD, 1575P NF1: 92IN NF2: 419PD NF-kB: 17IN, 66IN, 148P, 150P, 348P, 752, 807P, 1531P, 1680P NGF-B: 865P NK-1: 129IN NKG2D: 160P NMP-52: 239 NOS2: 1681P NOTCH1: 62IN, 216P, 448PD, 463P, 642, 720P, 996P NOXA: 66IN NPRA: 748 NQO1: 235 NRAS: 7IN, 119IN, 227P, 574P, 1649P NRP1: 1236PD NRP1: 546P NRP2: 915P NSE: 886, 911P, 1203P NTX: 132O, 1321 OCT-4: 149P, 720P OPN: 791PD, 833P Osteopontin: 833P p14: 543P, 1118PD p16: 86IN, 221P, 543P, 1018O, 1045P, 1118PD, 1211 p19: 150P P1NP: 805P, 945 p21: 575P P38: 348P, 1075P P40: 150P, 181P P4EBP1: 457P P4HB: 1701 p53: 7IN, 12IN, 20IN, 25IN, 50IN, 61IN, 62IN, 92IN, 93IN, 102IN, 156P, 170O, 180P, 187P, 291P, 575P, 615, 628, 675P, 686P, 703P, 979P, 1026P, 1031P, 1068PD, 1122P, 1192PD, 1311P, 1661P, 1662P P63: 1026P p70S6K: 236, 420PD P85: 419PD P95: 243, 267P, 347P PAI: 615 pAkt: 60IN, 154P, 343P, 405TiP, 406TiP, 442O, 443PD, 457P, 474P, 1026P, 1031P, 1668P, 1676P PAL1: 249PD PAM50: 176PD PAP: 943P ix606 | translational research index Volume 23 | Supplement 9 | September <strong>2012</strong>
Page 1 and 2:
Annals of Oncology www.annonc.oxfor
Page 3 and 4:
subscriptions A subscription to Ann
Page 6 and 7:
Annals of Oncology Official Journal
Page 8 and 9:
The European Society for Medical On
Page 10 and 11:
Audit Committee Chair: Fortunato Ci
Page 12 and 13:
Familial cancer Judith Balmaña, Ba
Page 14 and 15:
ESMO 2012 Congress Travel Grants 47
Page 16 and 17:
Exhibitors The following companies
Page 18 and 19:
ESMO Fellowships, 1989-2011 The Eur
Page 20:
Ondrej Gojis, Czech Republic 2008-2
Page 23 and 24:
abstracts hpv biology and implicati
Page 25 and 26:
abstracts the characterization of l
Page 27 and 28:
abstracts description of intra-tumo
Page 29 and 30:
prevent cell death. It is anticipat
Page 31 and 32:
22IN TARGETING THE HOST IN TNBC G.
Page 33 and 34:
abstracts a paradigm shift in early
Page 35 and 36:
abstracts how can medical oncologis
Page 37 and 38:
feasibility), but by how high the c
Page 39 and 40:
abstracts re-inventing the medical
Page 41 and 42:
abstracts emerging diagnostic and t
Page 43 and 44:
abstracts biologically based treatm
Page 45 and 46:
abstracts molecular targets in mali
Page 47 and 48:
abstracts melanoma therapy: from fr
Page 49 and 50:
diagnosis and can also be used for
Page 51 and 52:
analysis at 11 months median follow
Page 53 and 54:
mouse model of Kras mutant NSCLC. I
Page 55 and 56:
abstracts subtyping soft tissue sar
Page 57 and 58:
abstracts key topics in supportive
Page 59 and 60:
ESMO-CSCO Joint Symposium: Building
Page 61 and 62:
ESMO-EANM-ESR Joint Symposium: Imag
Page 63 and 64:
ESMO-ESTRO Joint Symposium: Innovat
Page 65 and 66:
ESMO-MASCC Joint Symposium: Integra
Page 67 and 68:
ESO Society Symposium: Celebrating
Page 69 and 70:
Results: TIMP-1 expression was incr
Page 71 and 72:
will benefit from this targeted the
Page 73 and 74:
cytomegalovirus (CMV). Analysis of
Page 75 and 76:
functional consequences of Endoglin
Page 77 and 78:
elationship between the ROR score,
Page 79 and 80:
183P EPIDERMAL GROWTH FACTOR RECEPT
Page 81 and 82:
Plasma adiponectin level on the pre
Page 83 and 84:
Table: 198P PFS OS Median, mo HR Me
Page 85 and 86:
204P EVALUATION OF PTEN AND PIK3CA
Page 87 and 88:
Material and methods: We searched P
Page 89 and 90:
Results: The median concentration o
Page 91 and 92:
Table: 226P Methods: Pts were rando
Page 93 and 94:
However, additional analysis sugges
Page 95 and 96:
number of biomarkers have been trie
Page 97 and 98:
Table: 248O 249PD PROTEOMIC PREDICT
Page 99 and 100:
Conclusions: BW and serum Ctrough o
Page 101 and 102:
261P BREAST CANCER SUBTYPES AND OUT
Page 103 and 104:
90 mg/m2-cyclophophamide 600 mg/m2
Page 105 and 106:
to 9 weeks after dosing. Trastuzuma
Page 107 and 108:
Patients and methods: We reviewed d
Page 109 and 110:
sector patients. The aim of this st
Page 111 and 112:
Linear Logistic Model with Relaxed
Page 113 and 114:
Results: The median CTC fold change
Page 115 and 116:
312: Table: Chemotherapy uptake wit
Page 117 and 118:
abstracts breast cancer, locally ad
Page 119 and 120:
Results: 8 trials (2092 pts) with 1
Page 121 and 122:
absolute difference of median value
Page 123 and 124:
Novartis, Genentech, and sanofi-ave
Page 125 and 126:
Results: Three RCTs with 1023 patie
Page 127 and 128:
collected from all patients for det
Page 129 and 130:
355P FIRST REPORT OF LONG-TERM RESP
Page 131 and 132:
361P A RETROSPECTIVE ANALYSIS OF PL
Page 133 and 134:
publications and aggregated in a me
Page 135 and 136:
Thus the primary aim to target BCSC
Page 137 and 138:
383 WHY DO WOMEN WITH BREAST CANCER
Page 139 and 140:
Results: We evaluated 76 pts with M
Page 141 and 142:
more than 6 cycles of capecitabine.
Page 143 and 144:
406TiP PHASE II TRIAL OF PRIMARY SY
Page 145 and 146:
abstracts CNS tumors 410O CONDITION
Page 147 and 148:
Conclusions: Our data suggested tha
Page 149 and 150:
Conclusions: As in other cancer typ
Page 151 and 152:
432 GAMMA KNIFE RADIOSURGERY AS A M
Page 153 and 154:
abstracts developmental therapeutic
Page 155 and 156:
1PR), but no responses were seen in
Page 157 and 158:
RO and Cd, as well as PD data for c
Page 159 and 160:
and vulvar Ca), and 11 SDs were obs
Page 161 and 162:
knowing HLA-A status double-blindly
Page 163 and 164:
Acquired-resistance to EGFR inhibit
Page 165 and 166:
474P PHASE 1 STUDY OF THE SELECTIVE
Page 167 and 168:
TST is active in breast and gastric
Page 169 and 170:
Treatment-induced shedding of circu
Page 171 and 172:
Methods: Either co-cultures of peri
Page 173 and 174:
501 PRECLINICAL DATA INVESTIGATING
Page 175 and 176:
509TiP LUX-LUNG 8: A RANDOMIZED, OP
Page 177 and 178:
(P = 0.64). Synchronous BBC was sig
Page 179 and 180:
abstracts gastrointestinal tumors,
Page 181 and 182:
Disclosure: M. Lee: I am an employe
Page 183 and 184:
plus intravenous Bev(7.5mg/kg q 21d
Page 185 and 186:
anti-EGFR treatment. The present st
Page 187 and 188:
patients harboring a T/T genotype t
Page 189 and 190:
551P ADJUVANT CHEMOTHERAPY (AC) USE
Page 191 and 192:
experienced significantly more ≥
Page 193 and 194:
functioning scales. Exploratory ana
Page 195 and 196:
oxaliplatin (100 mg/m 2 )/raltitrex
Page 197 and 198:
572P PANERB STUDY: WHICH CATEGORY O
Page 199 and 200:
Results: 92/114 patients were preop
Page 201 and 202:
585P CHANGES IN THE INTESTINAL ENVI
Page 203 and 204:
592P PHASE II TRIAL OF COMBINED CHE
Page 205 and 206:
minutes. In a previous study, 30-mi
Page 207 and 208:
Patients and methods: Chemotherapy-
Page 209 and 210:
612P ARE PATIENTS WITH RESECTABLE R
Page 211 and 212:
Conclusions: AMPK and ACC activatio
Page 213 and 214:
of surgical monotherapy in patients
Page 215 and 216:
Table: 632 633 AFLIBERCEPT/FOLFIRI
Page 217 and 218:
factors play the determining role i
Page 219 and 220:
Abstract withdrawn in exceptional c
Page 221 and 222:
were respectively 10.6 vs 8.5 vs 3.
Page 223 and 224:
Results: 20 gastrointestinal cancer
Page 225 and 226:
abstracts gastrointestinal tumors,
Page 227 and 228:
Day 8. A second identical course wa
Page 229 and 230:
proven in stage I GC. The aim of th
Page 231 and 232:
Conclusions: Longer OS to FOLFOX wa
Page 233 and 234:
692P PRELIMINARY SAFETY DATA FROM A
Page 235 and 236:
subgroup. Taking into consideration
Page 237 and 238:
Results: Three years of adjuvant im
Page 239 and 240:
considered sufficient to give an 80
Page 241 and 242:
721P FIRST-LINE TREATMENT WITH FOLF
Page 243 and 244:
after Gem-based therapy. The additi
Page 245 and 246:
735P RADIOGRAPHIC PARAMETERS IN PRE
Page 247 and 248:
validate the revised AJCC 7th stagi
Page 249 and 250:
Results: Among 862 MM we identified
Page 251 and 252:
Results: Frequently reported advers
Page 253 and 254:
gastric cancer patients with CNS me
Page 255 and 256:
discriminate the prognosis of HCC p
Page 257 and 258:
prospective, non-interventional stu
Page 259 and 260:
abstracts genitourinary tumors, non
Page 261 and 262:
787O EXTERNAL VALIDATION OF THE ASS
Page 263 and 264:
patient preference for P over S, an
Page 265 and 266:
798PD OPEN-LABEL PHASE II TRIAL OF
Page 267 and 268:
Hb, PS and LM. Median PFS for patie
Page 269 and 270:
may have led to reduced dose and sh
Page 271 and 272:
Results: 1,622 patients were identi
Page 273 and 274:
RCC) was designed to address an unm
Page 275 and 276:
Patients and methods: This is a sin
Page 277 and 278:
treatment at week 4, and week 12 by
Page 279 and 280:
effective in second or further line
Page 281 and 282:
Conclusions: In pts with RCC treate
Page 283 and 284:
using Drug inCode ® pharmacogeneti
Page 285 and 286:
Table: 857P standard, but is not av
Page 287 and 288:
efused HDCT. Of 23 patients, 20 com
Page 289 and 290:
we identified 49 and 220 patients w
Page 291 and 292:
879 TREATMENT OF PATIENTS WITH META
Page 293 and 294:
Median overall survival (OS) was 26
Page 295 and 296:
abstracts Genitourinary tumors, pro
Page 297 and 298:
and week 13 BPI-SF Q3 scores), 28%
Page 299 and 300:
Working Group (PCWG)-2 guidelines r
Page 301 and 302:
atio HR 0.39; CI 0.18, 0.83, p = 0.
Page 303 and 304:
We observed tumor responses and pro
Page 305 and 306:
Here we report emerging data from t
Page 307 and 308:
928P LHRH AGONIST-INDUCED SUPPRESSI
Page 309 and 310:
Disclosure: S. Oudard: Has acted as
Page 311 and 312:
939P NEOADJUVANT SIPULEUCEL-T IN LO
Page 313 and 314:
945 BONE TURNOVER MARKERS AND POTEN
Page 315 and 316:
952 SEQUENTIAL ANDROGEN DEPRIVATION
Page 317 and 318:
managed in a multidisciplinary (MD)
Page 319 and 320:
or hypercalcemia at screening; prio
Page 321 and 322:
meeting. The prevalence of LGSC is
Page 323 and 324:
Table: 975PD Continued AMG 386 + pa
Page 325 and 326:
physicians in the U.S. and Europe.
Page 327 and 328:
989P PHASE II STUDY OF COMBINATION
Page 329 and 330:
elated with stage, nodal involvemen
Page 331 and 332:
1004P CASE CONTROL STUDY ON TWO DIF
Page 333 and 334:
eight patients who had infertility
Page 335 and 336:
abstracts head and neck cancer 1016
Page 337 and 338:
same CT/RT; Arm B2: 3 cycles of ind
Page 339 and 340:
induction chemotherapy in the treat
Page 341 and 342:
patients. We have developed a rando
Page 343 and 344:
evaluated by the screening instrume
Page 345 and 346:
morbidities that radiation would le
Page 347 and 348:
Conclusions: Through adequate selec
Page 349 and 350:
abstracts hematological malignancie
Page 351 and 352:
anthracyclines in vitro. A favorabl
Page 353 and 354:
1076P RITUXIMAB PLUS SUBCUTANEOUS C
Page 355 and 356:
than the standard target of ≥2.5
Page 357 and 358:
Patients: From November 2002 to May
Page 359 and 360:
lymphadenopathy and multiple cutane
Page 361 and 362:
prospective non-interventional stud
Page 363 and 364:
Funding: GSK Biologicals Disclosure
Page 365 and 366:
survival rates of 13-25% (Prieto et
Page 367 and 368:
high response rates and prolonged p
Page 369 and 370:
GlaxoSmithKline, Merck Sharp & Dohm
Page 371 and 372:
advisor for Merck Sharp & Dohme, an
Page 373 and 374:
or cutaneous melanoma. A survival u
Page 375 and 376:
systemic therapy or were intolerant
Page 377 and 378:
abstracts neuroendocrine tumors and
Page 379 and 380:
morbidity, with G3 tumors behaving
Page 381 and 382:
pts. Poorly differentiated endocrin
Page 383 and 384:
Adenocarcinoma was present in 25 pa
Page 385 and 386:
Method: Endobronchial ultrasound gu
Page 387 and 388:
widely used by single agent or plat
Page 389 and 390:
disease after surgery were treated
Page 391 and 392:
stage IIIA NSCLC, EML4-ALK fusion-p
Page 393 and 394:
1200P CONCOMITANT CHEMORADIATION GI
Page 395 and 396:
Patients and methods: The study was
Page 397 and 398:
months (95% CI:13-25). The PFS and
Page 399 and 400:
maintenance therapy had favourable
Page 401 and 402:
abstracts non-small cell lung cance
Page 403 and 404:
Ingelheim, GSK Biologicals (compens
Page 405 and 406:
1234PD RANDOMIZED PHASE III TRIAL O
Page 407 and 408:
GlaxoSmithKline (myself, compensate
Page 409 and 410:
1243P IDENTIFICATION OF MICRORNA (M
Page 411 and 412:
N-arm n=34 P-arm n=32 All n=66 Male
Page 413 and 414:
1255P POPULATION BASED EVALUATION O
Page 415 and 416:
1262P DISTINCT SPREAD OF EGFR MUTAT
Page 417 and 418:
1268P VISUAL DISTURBANCES IN PATIEN
Page 419 and 420:
MERCK SERONO: Advisor, speaker in s
Page 421 and 422:
Conclusions: These data from SAiL a
Page 423 and 424:
NSCLC diagnosis and time of BM diag
Page 425 and 426:
1291P PHASE I/II DOSE-FINDING STUDY
Page 427 and 428:
Network utilization of WBCGF in the
Page 429 and 430:
1303P COST EFFECTIVENESS OF PEMETRE
Page 431 and 432:
Results: The patients’ characteri
Page 433 and 434:
EGFR mut at exons 18, 19, 21, and K
Page 435 and 436:
Methods: EML4-ALK fusion was screen
Page 437 and 438:
Results: The median survival time (
Page 439 and 440:
enefit from sustained EGFR blockade
Page 441 and 442:
epresented by 19 pts (32%) female,
Page 443 and 444:
and at least one prior course of ch
Page 445 and 446:
Methods: NSCLC patients with radiog
Page 447 and 448:
1367TiP LONG-TERM ERLOTINIB THERAPY
Page 449 and 450:
Austria, Czech Republic, Finland, G
Page 451 and 452:
were every 6 weeks (wk) (S1), every
Page 453 and 454:
Advantage enrollees (83% vs. 25%) [
Page 455 and 456:
Results: Based on 10,000 simulation
Page 457 and 458:
cancer tumors 12%, Germ cell tumor
Page 459 and 460:
Material and methods: 50 lung cance
Page 461 and 462:
1414TiP IMPLEMENTATION OF CANCER RE
Page 463 and 464:
abstracts palliative care 1422O EFF
Page 465 and 466:
Method and results: A total of 317
Page 467 and 468:
1436P SURVEY ON MODELS OF INTEGRATI
Page 469 and 470:
care unit (PCU) at the National Can
Page 471 and 472:
Characteristic No. % Total 63 1 st
Page 473 and 474:
hysterectomised-9.10% and cervix ca
Page 475 and 476:
abstracts psycho-oncology 1462PD IN
Page 477 and 478:
events, tumour response, and surviv
Page 479 and 480:
abstracts sarcoma 1477O ADHESION TO
Page 481 and 482:
1481PD A PHASE II STUDY OF DOVITINI
Page 483 and 484:
1488P ORGANISATION OF SARCOMA PATIE
Page 485 and 486:
Patients and methods: From August 2
Page 487 and 488:
chemotherapy respectively. At a med
Page 489 and 490:
of this group Those with relapsed d
Page 491 and 492:
1515 PREDICTORS OF SURVIVAL IN ADOL
Page 493 and 494:
abstracts small cell lung cancer an
Page 495 and 496:
emaining receiving either CAV or to
Page 497 and 498:
1533P EXPRESSION OF WILM⍰TUMOUR G
Page 499 and 500:
more than 3 months after first line
Page 501 and 502:
lower recurrence rate of NE. Pegfil
Page 503 and 504:
egimens (HR = 2.5, p < 0.001). Phys
Page 505 and 506:
1561P PREDICTIVE DIAGNOSTICS FOR RE
Page 507 and 508:
Methods: A prospective multicentre
Page 509 and 510:
Table: 1574P Pharmacokinetic parame
Page 511 and 512:
Novartis and unrestricted research
Page 513 and 514:
studies have shown that chemotherap
Page 515 and 516:
(Grade 1) and moderate to severe (G
Page 517 and 518:
declined to relatively lower level
Page 519 and 520:
1609P PHYSICAL ACTIVITY (PA) AND PH
Page 521 and 522:
patients were admitted to the oncol
Page 523 and 524:
Dicarbamin 100 mg/day on day 5 befo
Page 525 and 526:
Results: Anemia was detected in 83.
Page 527 and 528:
important to carry out randomized s
Page 529 and 530:
abstracts translational research 16
Page 531 and 532:
expression. Then, we analyzed PB sa
Page 533 and 534:
Table: 1657P TH BV + TH HR (95% CI)
Page 535 and 536:
BRAF mutations. Circulating free DN
Page 537 and 538:
1671P PHASE I CLINICAL TRIAL OF CAN
Page 539 and 540:
1678P PREDICTIVE VALUE OF TWO PHENO
Page 541 and 542:
theorized that the PI3K/AKT pathway
Page 543 and 544:
Material and methods: 101 patients
Page 545 and 546:
overexpressing and 232 had triple n
Page 547 and 548:
author index author index A Aamdal
Page 549 and 550:
author index Badran A. ix288 (874)
Page 551 and 552:
author index Bösmüller H. ix209 (
Page 553 and 554:
author index Chen A. ix319 (966O) C
Page 555 and 556: author index De Droogh E. ix452 (13
Page 557 and 558: author index Esposito G. ix209 (618
Page 559 and 560: author index Geiges G. ix306 (930P)
Page 561 and 562: author index Hartono S. ix70 (155P)
Page 563 and 564: author index Iwasaki H. ix542 (1694
Page 565 and 566: author index Kodaira M. ix90 (228P)
Page 567 and 568: author index Lichtensztejn D. ix350
Page 569 and 570: author index Martinez A. ix496 (153
Page 571 and 572: author index Morishita N. ix432 (13
Page 573 and 574: author index Okamoto N. ix432 (1320
Page 575 and 576: author index Piau S. ix456 (1401P)
Page 577 and 578: author index Rodríguez Rodríguez
Page 579 and 580: author index Scoggins C.R. ix371 (1
Page 581 and 582: author index Stern L. ix272 (823P)
Page 583 and 584: author index Trypaki M. ix429 (1308
Page 585 and 586: author index Whitmore J.B. ix310 (9
Page 587 and 588: subject index subject index A AAV-H
Page 589 and 590: subject index ix115 (316TiP), ix116
Page 591 and 592: subject index diffuse large B-cell
Page 593 and 594: subject index (1033P), ix340 (1036P
Page 595 and 596: subject index medical information,
Page 597 and 598: subject index (612P), ix214 (633),
Page 599 and 600: subject index RCC, ix274 (830P) re-
Page 601 and 602: subject index TR-FRET, ix84 (206P)
Page 603 and 604: drug index drug index 1248P, 1250P,
Page 605: translational research index transl
Page 609: translational research index transl
show all

Download the ESMO 2012 Abstract Book - Oxford Journals

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?